Pfizer Animal Health has gained full licensure from the U.S. Department of Agriculture (USDA) for FluSure Pandemic. The vaccine aims to help pork producers protect their herds from the pandemic H1N1 (pH1N1) strain of swine influenza virus (SIV).
Pfizer Animal Health was the first manufacturer to gain a conditional vaccine license for this new flu strain in 2009. Since that time, Pfizer has conducted additional research to further support product safety and efficacy.
“In a challenge study, the vaccine helped reduce both viral shedding and lung lesions,” says Michael Kuhn, DVM, manager, veterinary operations for Pfizer Animal Health.
The new vaccine adds another valuable SIV management tool to the company’s FluSure XP Defense System.
“Pfizer Animal Health is committed to monitoring swine influenza viruses and bringing to the market vaccines that help protect against SIV strains circulating in pork production systems today,” says Kuhn.
FluSure Pandemic is labeled for vaccination of healthy swine, including pregnant sows and gilts, at three weeks of age or older to aid in preventing nasal shedding and reducing lung lesions caused by the SIV subtype pH1N1. The vaccine comes in 50-dose and 250-dose sizes.
Amphigen is the adjuvant used in FluSure Pandemic. It helps stimulate immune responses using the animal’s natural defense system to help fight disease.
Producers should consult their veterinarian as well as follow American Association of Swine Veterinarians and National Pork Producers Council recommendations for routine flu preventive measures.
For more information, visit www.PfizerAH.com